Zhejiang Tianyuan Biopharmaceutical Files IPO Prospectus Following GSK's Former Ownership and Launch of Quadrivalent Influenza Vaccine

Introduction: "In the vast field of biopharmaceutical vaccines, one company shines like a brilliant star.——Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.，Its quality system construction is executed according to the standards of internationally renowned multinational companies (Novartis, GSK).As early as 2009RuiSinoNovo Acquires 85% of Tianyuan's Equity, 2015GSK's Setfirst Limited Acquires Tianyuan,Continued to invest heavily approximately 9.5 billion yuan in upgrading products and plant facilities,To become a vaccine production enterprise in China that can currently produce according to EU standards, possessing international leadership.2017GSK Decides to Sell 100% Equity of Tianyuan Bio. Sold in 2019 toNanjing Huapai Biotechnology, 2021Shandong Buchang Pharmaceutical Increases Capital and AchievesAbsolute Controlling Interest，Holding ratio 54.4%"

Recent developments at Buchang PharmaceuticalAnnouncement Release, Controlling SubsidiaryZhejiang Tianyuan BioPharmaceutical Co., Ltd. recently received the approval issued by the National Medical Products AdministrationQuadrivalent InfluenzaDrug Registration Certificate for Virus Lytic Vaccine. This vaccine is mainly used to stimulate the body to produce immunity against the influenza virus, in order to prevent influenza caused by this virus strain.The company's R&D expenses for this project are approximately 126 million yuan.

According to the announcement, the drug approval number for the quadrivalent influenza virus split vaccine is S20250038, and its validity period extends until July 7, 2030. This vaccine is a prescription drug and falls under the registration category of preventive use.Biological Products，The production enterprise and marketing authorization holder are both Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.

Technology Platform:

Tianyuan Bio has built three major R&D platforms: bacterial vaccines, viral vaccines, and recombinant vaccines.

Products under development:

• Covering the full range of influenza virus vaccines(Trivalent egg-based influenza vaccine, quadrivalent egg-based influenza vaccine, CpG adjuvanted quadrivalent influenza vaccine, MDCK cell-based quadrivalent influenza vaccine, and recombinant influenza virus vaccine)

• Viral vaccines based on human diploid cells(Varicella Attenuated Vaccine, Rabies Inactivated Vaccine)

• Recombinant Protein Vaccines Based on Genetic Engineering Platform(Herpes Zoster Vaccine, COVID-19 Vaccine, Recombinant Multivalent Norovirus Vaccine, Hand-Foot-Mouth Vaccine, HPV Vaccine, Recombinant Group B Meningococcal Vaccine)Multivalent Combined Vaccines